Cargando…

ID2 and HIF-1α collaborate to protect quiescent hematopoietic stem cells from activation, differentiation, and exhaustion

Defining mechanism(s) that maintain tissue stem quiescence is important for improving tissue regeneration, cell therapies, aging, and cancer. We report here that genetic ablation of Id2 in adult hematopoietic stem cells (HSCs) promotes increased HSC activation and differentiation, which results in H...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubison, Brad L., Sarkar, Tanmoy, Gudmundsson, Kristbjorn O., Singh, Shweta, Sun, Lei, Morris, Holly M., Klarmann, Kimberly D., Keller, Jonathan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246389/
https://www.ncbi.nlm.nih.gov/pubmed/35775482
http://dx.doi.org/10.1172/JCI152599
Descripción
Sumario:Defining mechanism(s) that maintain tissue stem quiescence is important for improving tissue regeneration, cell therapies, aging, and cancer. We report here that genetic ablation of Id2 in adult hematopoietic stem cells (HSCs) promotes increased HSC activation and differentiation, which results in HSC exhaustion and bone marrow failure over time. Id2(Δ/Δ) HSCs showed increased cycling, ROS production, mitochondrial activation, ATP production, and DNA damage compared with Id2(+/+) HSCs, supporting the conclusion that Id2(Δ/Δ) HSCs are less quiescent. Mechanistically, HIF-1α expression was decreased in Id2(Δ/Δ) HSCs, and stabilization of HIF-1α in Id2(Δ/Δ) HSCs restored HSC quiescence and rescued HSC exhaustion. Inhibitor of DNA binding 2 (ID2) promoted HIF-1α expression by binding to the von Hippel-Lindau (VHL) protein and interfering with proteasomal degradation of HIF-1α. HIF-1α promoted Id2 expression and enforced a positive feedback loop between ID2 and HIF-1α to maintain HSC quiescence. Thus, sustained ID2 expression could protect HSCs during stress and improve HSC expansion for gene editing and cell therapies.